OCT 07, 2017 1:49 PM PDT

Defective Viral Genomes Help Infections Linger

WRITTEN BY: Kara Marker

Cells that are infected with a virus sacrifice themselves, dying before the virus has a chance to use the cell’s own machinery to replicate and spread to other cells. This is why viral infections like respiratory syncytial virus (RSV), measles, parainfluenza, and Ebola are acute, not long-lasting. But when viruses find a way to linger in their host’s cells without being killed by the immune system, the infection transforms from acute to chronic, causing multiple complications.

Making insights into how virus-infected cells can survive the onslaught of an immune response, researchers have found that cells enriched with defective viral genomes (in green) had strategies to persist, unlike cells with more full-length viral genomes (in orange/yellow). Credit: University of Pennsylvania

In a new Nature Communications study, researchers from the University of Pennsylvania identify a mechanism responsible for viruses overstaying their welcome in the human body. The culprit? Defective viral genomes.

As a virus invades the body and begins to mass-produce itself by manipulating the replication machinery of the body’s own cells, the virus can make mistakes while replicating the genome, leading to defective viral genomes (DVGs) present in some cells. Senior author of the new study, Carolina B. López, has researched DVGs for a long time. Interestingly, DVGs simultaneously instigate an immune response to the virus and stimulate a molecular pathway that prevents infected cells from self destruction.

“DVGs promote persistent infections in tissue culture," López explained. "How do you reconcile that with the fact that they're also very immunostimulatory? How can they help clear virus at the same time as they promote persistence? Our work helps explain this apparent paradox."

In her newest study, López and her team of researchers observed DVGs in cells, picking apart the cells with full-length genomes, the cells with DVGs, and the cells with some of each. Then, researchers infected healthy cells with either RSV or the Sendai virus, looking at the difference when viruses were DVG-deficient versus DVG-rich.

In their study, researchers used Respiratory Syncytial Virus (pictured) and the Sendai virus, also known as murine parainfluenza virus type 1, is an RNA virus not pathogenic to humans. It was first isolated in the 1950s in Japan and has been used ever since as a tool in the research lab.

Researchers observed cells infected with DVG-rich virus surviving significantly longer than those with DVG-deficient viruses, confirming that DVGs were directly involved in the survival of virally-infected cells.

How exactly are DVG-rich virally-infected cells avoiding apoptosis? A gene expression analysis revealed that “pro-survival genes” are very active in DVG-rich cells.

“These data show that our cells are wired to survive if they are engaged in an antiviral response, explaining the paradoxical functions of DVGs,” Lopez explained. “It seems that in order to persist, the virus is taking advantage of these host pathways that are there to promote the survival of cells working to eliminate the virus."

Now that Lopez knows how viruses are able to linger in the body, she hopes to find a way to prevent this from happening. "I want to see if there's a way we can harness this pathway to minimize and avoid the persistence of these viruses.”

Sources: Current Gene Therapy, University of Pennsylvania

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 20, 2020
Health & Medicine
MAR 20, 2020
Why Does COVID-19 Kill So Many Older People?
Since early statistics began to emerge from China, it seemed that COVID-19 tended to affect older people more than young ...
APR 02, 2020
APR 02, 2020
Transforming T Cells into Powerful Memory Cells That Target Cancer
New cancer treatments are now based on harnessing the power of the human body’s own immune cells to get the job do ...
APR 06, 2020
APR 06, 2020
Clearing the Path for Dendritic Cells to Eliminate Tumors
  Dendritic cells are the sentinels of the immune system and use their “tree-like” projections to prese ...
APR 07, 2020
APR 07, 2020
Second COVID-19 Vaccine Enters Human Trials
Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19.
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Gilead's Remdesivir Trial Sees Rapid Recoveries from COVID-19
Early results from a Chicago hospital treating patients with Gilead Sciences’ antiviral drug remdesivir for severe ...
MAY 16, 2020
MAY 16, 2020
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
Researchers at McLean Hospital and Massachusetts General Hospital (MGH) have tested a stem cell treatment method that av ...
Loading Comments...